Gemcitabine, navelbine, and therarubicin (GNT) as treatment for patients with refractory or relapsed T-cell lymphoma
10.3969/j.issn.1000-8179.20140559
- VernacularTitle:吉西他滨长春瑞滨联合吡喃阿霉素方案治疗复发难治T细胞淋巴瘤疗效分析
- Author:
Shaohua WU
;
Huaqing WANG
;
Zhengzi QIAN
;
Huilai ZHANG
;
Shiyong ZHOU
;
Lihua QIU
;
Zheng SONG
;
Xianhuo WANG
- Publication Type:Journal Article
- Keywords:
gemcitabine;
T-cell lymphoma;
navelbine;
therarubicin
- From:
Chinese Journal of Clinical Oncology
2014;(10):647-650
- CountryChina
- Language:Chinese
-
Abstract:
Objective:This study was conducted to evaluate and discuss the curative effect and toxicity of gemcitabine, navel-bine, and therarubicin (GNT) regimen for patients with refractory or relapsed T-cell lymphoma (TCL). Methods:A total of 69 patients with refractory or relapsed TCL treated with GNT were enrolled. The treatment protocol was set as follows:800 mg/m2 gemcitabine ad-ministered at 1 and 8 d;25 mg/m2 navelbine administered at 1 d;and 20 mg/m2 therarubicin administered at 1 d. This protocol was re-peated every three weeks. The median cycle was 4 (range:2 to 6). Results:The overall response rate was 65.2%and the achieved com-plete remission was 29.0%. Hematology toxicities were the main adverse reactions observed in all of the patients. The incidence rates of grades 1 and 2 toxicity in leukopenia or neutropenia, anemia, and thrombocytopenia were 50.7%, 33.3%, and 26.1%, respectively. Grades 3 and 4 treatment-associated toxicities were detected in 23.1%of the responding patients. One-, three-, and five-year estimated overall survival (OS) of the whole cohort were 71.7%, 47.3%, and 32.4%, respectively. The median OS was 36 months. Conclusion:GNT was effective and suitable for patients with refractory or relapsed TCL.
